LexaGene Holdings Inc.: going-concern / distress — LexaGene files for Chapter 7 bankruptcy, ceases operations and lays off staff

LexaGene Holdings Inc.

Filed voluntary Chapter 7 petition in U.S. Bankruptcy Court for District of Massachusetts on Feb 24, 2023.
Company ceased operations and laid off all staff; federal trustee will liquidate assets.
CEO cites inability to secure funding, market conditions, and slow biopharma sales cycle.
No liquidation proceeds expected to satisfy all creditors; shareholders unlikely to receive any distribution.
Subsidiaries LexaGene, Inc. and Bionomics Diagnostics, Inc. included in filing.

Key facts

Extracted from this filing and checked against the source text.

Distress & Bankruptcy SEC 8-K Item 1.03 confidence 0.95

LexaGene Holdings Inc. entered chapter 7 in United States Bankruptcy Court for the District of Massachusetts (petition 2023-02-24).

Proceeding: chapter 7
Court: United States Bankruptcy Court for the District of Massachusetts
Petition: 2023-02-24

Exact text from the filing

On February 24, 2023, LexaGene Holdings Inc. (the “ Company ”) filed for liquidation under Chapter 7 of Title 11 of the United States Code (the “ Bankruptcy Code ”) in the United States Bankruptcy Court for the District of Massachusetts (the “ Bankruptcy Court ”), located in Boston, Massachusetts.

View on SEC.gov

Browse all distress & bankruptcy →

Source: SEC EDGAR

accession 0001104659-23-025001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.